



4<sup>th</sup> Annual

# HEART IN DIABETES


*Where the Heart, Kidney and Diabetes Meet in Clinical Practice*

**FREE**

**LIVE INTERACTIVE ONLINE**

EARN  
**FREE**  
CME  
ACCME  
CREDITS  
28.00

## AUGUST 21-24, 2020



All content available ON-DEMAND for 90 DAYS following the meeting

[www.HEARTINDIABETES.com](http://www.HEARTINDIABETES.com)

Jointly Provided By:



Administered By:



@heartindiabetes



#### 4th Heart in Diabetes Welcome Letter (Virtual):

We invite you to join us for the 4th Annual Heart in Diabetes (HiD) Live Interactive Online Medical Conference to be held from August 21-24, 2020. Following the conference, all content will be available on demand for 90 days. 4th HiD live virtual registration is FREE. Click [here](#) to register. Attendees may earn up to 28 FREE CME

Heart in Diabetes is a medical conference representing an educational initiative, which is a combined effort of cardiologists and endocrinologists. To date, the HiD congress has been a rousing success, with progressive growth of participants and impressive evaluations. Overall, attendees at the 3rd annual conference rated the congress a 3.04 out of 4 in terms of overall quality, educational content, and positive impact on knowledge and professional effectiveness.

The 4th Annual Heart in Diabetes (HiD) will convene expert faculty and practicing clinicians in a one-of-a-kind virtual scientific conference to share knowledge and best practices for managing patients with diabetes, heart disease, and various cardiometabolic conditions. Since 2017, this unique forum has enabled clinicians to improve care for patients with diabetes and obesity who have cardiovascular disease and/or chronic kidney disease, often with heart failure. These disorders share many pathological features and often occur in the same individual. Until recently, however, they were managed by different specialists with varying clinical priorities and goals. The strength of HiD is the promotion and development of cross-discipline approaches to the management of these conditions.

Recent trials have demonstrated cardiovascular benefits from agents that control glycemia, lipids, blood pressure, and inflammation in people with diabetes. However, among practicing professionals, including experts, there is a gap in understanding the implications of these new developments in disease management. The conference examines the newest outcome data and develops suggestions for clinicians and recommendations on the proper implementation of the studies results in practice.

HiD is an all "state-of-the-art" clinical program. The agenda will feature an award presentation "Luminary in Cardiometabolic Medicine" to Dr. Eugene Braunwald, who will provide a keynote lecture. This program provides up-to-date clinical science of the Heart in Diabetes through a multidisciplinary interpretation of outcome data and its implications for practice; this from cardiology, endocrine/diabetes, and nephrology points of view. The virtual conference will include joint sessions with Circulation and JACC (Journal of the American College of Cardiology). In addition, the conference will cover sessions on COVID-19 in Diabetes & CVD, Women & CVD, Contemporary Concepts & Management of DM & ASCVD, The Kidney, Technology & Digital Health, Lipids, Antithrombotics in Diabetes, The Liver, Managing Hyperglycemia, Treatment of Diabetes, Heart Failure and will cover Guidelines and Practice Recommendations. The 4th HiD will also feature several virtual abstract presentations from scientists and researchers around the world as well as several Non-CME Industry Supported presentations.



**Yehuda Handelsman,**  
MD, FACP, FNLA, FASPC, MACE



**Mikhail N. Kosiborod,**  
MD, FACC, FAHA

## Heart in Diabetes (HiD) Scientific Committee

**Yehuda Handelsman, MD**  
Chair

Tarzana, California

**Mikhail N. Kosiborod, MD**  
Chair

Kansas City, Missouri

**Deepak L. Bhatt, MD**  
Boston, Massachusetts

**Zachary T. Bloomgarden, MD**  
New York, New York

**Biykem Bozkurt, MD, PhD**  
Houston, Texas

**Matthew J. Budoff, MD**  
Los Angeles, California

**Javed Butler, MD**  
Jackson, Mississippi

**David Cherney, MD, PhD**  
Toronto, Canada

**Robert J. Chilton, DO**  
San Antonio, Texas

**Mark E. Cooper, AO, PhD**  
Melbourne, Australia

**Michael H. Davidson, MD**  
Chicago, Illinois

**Ralph A. DeFronzo, MD**  
San Antonio, Texas

**Stefano Del Prato, MD**  
Pisa, Italy

**Daniel Einhorn, MD**  
San Diego, California

**Michael E. Farkouh, MD**  
Toronto, Canada

**Sergio Fazio, MD, PhD**  
Portland, Oregon

**Vivian A. Fonseca, MD**  
New Orleans, Louisiana

**Alan J. Garber, MD, PhD**  
Houston, Texas

**Peter J. Grant, MD**  
Leeds, United Kingdom

**George Grunberger, MD**  
Bloomfield Hills, Michigan

**Mansoor Husain, MD**  
Toronto, Canada

**Silvio E. Inzucchi, MD**  
New Haven, Connecticut

**Paul S. Jellinger, MD**  
Hollywood, Florida

**Mark Kearney, MD**  
Leeds, United Kingdom

**Lawrence A. Leiter, MDCM**  
Toronto, Canada

**Norman E. Lepor, MD**  
Los Angeles, California

**Derek LeRoith, MD, PhD**  
New York, New York

**Christos S. Mantzoros, MD, PhD**  
Boston, Massachusetts

**Nikolaus Marx, MD**  
Aachen, Germany

**Darren K. McGuire, MD**  
Dallas, Texas

**Christian W. Mende, MD**  
San Diego, California

**Richard E. Pratley, MD**  
Orlando, Florida

**Kausik Ray, MD, MPhil**  
London, United Kingdom

**Peter Reaven, MD**  
Phoenix, Arizona

**Benjamin M. Scirica, MD**  
Boston, Massachusetts

**Laurence Sperling, MD**  
Atlanta, Georgia

**Matthew R. Weir, MD**  
Baltimore, Maryland



## PROGRAM DESCRIPTION:

This CME conference is a unique medical meeting that brings world-renowned clinical leaders in diabetes and cardiovascular disease and practicing clinicians together to improve the care of patients at a high risk of cardiovascular, metabolic, and kidney diseases. This program is designed to evaluate the clinical science aspects of diabetes, obesity, and CVD, focusing on the heart and kidney in diabetes. The goal is to develop appropriate, comprehensive clinical management plans aligning endocrinologists, cardiologists, nephrologists and all other interested clinicians in their understandings of the impact of diabetes and CVD outcome trials on the clinical management of these very high-risk patients.

**PROGRAM OBJECTIVES:** Upon completion of this meeting, participants should be able to:

- Discuss the role of incretins in the management of obesity, diabetes, and its complications
- Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1-RAs to reduce cardiovascular mortality in patients with T2D
- Evaluate the evidence supporting the use of SGLT2 inhibitors for HF prevention
- Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
- Evaluate the extent of macro and microvascular disease in diabetes and obesity
- Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as glucose
- Discuss changes in lipid management guidelines
- Evaluate the impact on the clinical practice of new CV outcome trials in patients with diabetes, including CANVAS, LEADER, SUSTAIN 6, and EMPA-REG
- Evaluate the impact on the clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
- Implement the best practices for the management of HFrEF
- Describe the relationship between diabetes, obesity, and congestive heart failure
- Describe the role of PCSK9 in lipid elevations and their potential contributions to vascular disease
- Understand the mechanism of action of PCSK9 inhibitors and CETP inhibitors and their impact on CVD
- Design appropriate insulin-based therapeutic regimens for patients with type 2 diabetes
- Describe obesity management based on a complications-centric model
- Evaluate bariatric procedures and surgery as well as devices, and their effect on weight loss, hormones, and long-term outcomes
- Describe optimal use of glucose monitoring devices

### TARGET AUDIENCE

This educational initiative is designed for endocrinologists, cardiologists, diabetologists, nephrologists, internists, family physicians, nurse practitioners, physician assistants, and other healthcare professionals interested in the prevention and treatment of diabetes, obesity, cardiovascular disease, and associated conditions, as well as the effect of these conditions on health and society.

## THE HID SCIENTIFIC COMMITTEE GRATEFULLY ACKNOWLEDGES

### CORPORATE SUPPORT

Sapphire: **ESPERION**

Emeral: **AMARIN • ASTRAZENECA • BI/LILLY**

### UNRESTRICTED EDUCATIONAL GRANTS

Premier Educator: **ASTRAZENECA**

Leader Educator: **AMGEM**

Major Educators: **ABBOTT • PFIZER/MERCK ALLIANCE • NOVO NORDISK**

Educator: **LILLY USA • AMARIM PHARMA INC**

# PROGRAM 2020

FRIDAY AUGUST 21, 2020

Welcome & Introduction

Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD

## SESSION 1

### COVID-19 IN DM & CVD

Chair: Derek LeRoith, MD, PhD

10:00am – 10:20am  
10:20am – 10:40am  
10:40am – 11:00am  
11:00am – 11:20am  
11:20am – 11:40am  
11:40am – 12:00pm

Obesity, a Major Predictor of Mortality by COVID-19: Associations with DM & CVD and Implications for Therapy  
CVD Incidence & MOA in COVID-19: Vascular, Inflammatory & Thrombosis Implications  
Ongoing Research of COVID-19 Complications & Management - Focus on DARE-19  
Diabetes and the COVID-19 Pandemic  
The Impact of COVID-19 on Cardiovascular Care & the Post-Pandemic Future of Cardiovascular Prevention  
Panel Discussion & Live Q&A

Christos S. Mantzoros, MD, PhD  
Mansoor Husain, MD  
Mikhail N. Kosiborod, MD  
Zachary Bloomgarden, MD  
Laurence Sperling, MD

## SESSION 2

### CONTEMPORARY CONCEPTS & MANAGEMENT OF DM & ASCVD

Chair: Laurence Sperling, MD

12:00pm – 12:20pm  
12:20pm – 12:40pm  
12:40pm – 1:00pm  
1:00pm – 1:20pm

Epigenetic Modification to Reduce CVD in People with DM  
The Surgical Management of CAD in DM  
Update on CVOTs  
Panel Discussion & Live Q&A

Kausik Ray, MD  
Michael E. Farkouh, MD  
Michael H. Davidson, MD

## 1:20PM – 2:05PM

### PRODUCT THEATER Non-CME Industry Supported Session

TBD

Supported by: Amarin

Yehuda Handelsman, MD



## SESSION 3

### CONTROVERSIES IN LIPID MANAGEMENT

Chair: Paul S. Jellinger, MD • Kausik Ray, MD

2:05pm – 2:25pm  
2:25pm – 2:45pm

"Back to the Future" with Lipid Therapy  
Should High Triglycerides Be Managed in Addition to a Statin & EPA?

Norman E. Lepor, MD  
Sergio Fazio, MD, PhD

### DEBATE: SHOULD TREATMENT WITH PCSK9I BE RESERVED FOR LDL > 100

2:45pm – 3:00pm  
3:00pm – 3:15pm  
3:15pm – 3:20pm  
3:20pm – 3:25pm  
3:25pm – 3:45pm

Yes  
No  
Rebuttal  
Rebuttal  
Panel, Q&A, Audience Voting

Jennifer G. Robinson, MD  
Steven E. Nissen, MD

## SESSION 4

### HEART IN DIABETES WITH CIRCULATION

Chairs: Biykem Bozkurt, MD, PhD

3:45pm – 3:50pm  
3:50pm – 4:05pm  
4:05pm – 4:20pm  
4:20pm – 4:35pm  
4:35pm – 4:50pm  
4:50pm – 5:05pm  
5:05pm – 5:25pm

Introduction  
GLP1ra Exenatide and Heart Failure Outcomes  
The Diabetes Paradox in Aortic Aneurysm  
Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of CVD in T1DM  
Heart Failure Risk Stratification and Efficacy of SGLT2i in Patients with T2DM  
Sugar and Artificially-Sweetened Beverages and CVD Risk - Reason for Concern?  
Panel, Live Q&A

Biykem Bozkurt, MD, PhD  
Robert J. Mentz, MD  
Joshua Beckman, MD  
Myra A. Lipes, MD  
Benjamin M. Scirica, MD  
Alice H. Lichtenstein, D.Sc.

## 5:25PM – 6:15PM

### DAY 1 SUMMARY, LIVE Q&A

SATURDAY AUGUST 22, 2020

## SESSION 5

### WOMEN & CVD

Chairs: Norman E. Lepor, MD

10:00am – 10:20am  
10:20am – 10:40am  
10:40am – 11:00am  
11:00am – 11:20am

Cardiovascular Disease Risk Reduction in Menopausal Women  
Gender Differences in Cardiovascular Imaging  
Sex Differences in DM & CVD Across Outcome Studies  
Panel Discussion & Live Q&A

Gina P. Lundberg, MD  
Matthew J. Budoff, MD  
Neha J. Pagidipati, MD

## SESSION 6

### ADVANCES IN ANTI-THROMBOTICS IN DIABETES

Chairs: Deepak L. Bhatt, MD

11:20am – 11:40am  
11:40am – 12:00pm  
12:00pm – 12:20pm  
12:20pm – 12:40pm

Insights on Anti-thrombotic Strategies in Diabetes from THEMIS and THEMIS PCI  
Anti-thrombotic Therapy in Diabetes  
COMPASS  
Panel Discussion & Live Q&A

Philippe Gabriel Steg, MD  
Richard C. Becker, MD  
Deepak L. Bhatt, MD

**12:40PM**

**AWARD PRESENTATION "LUMINARY IN CARDIOMETABOLIC MEDICINE"**

**Presented by:** Deepak L. Bhatt, MD • Mikhail N. Kosiborod, MD • Yehuda Handelsman, MD

**12:45PM**

**KEY NOTE: SGLT2i and the Birth of 2 PARADIGM SHIFTS in Clinical Care**

**1:15PM**

**LIVE Q&A**

**Eugene Braunwald, MD**



**1:30PM – 2:15PM**

**PRODUCT THEATER Non-CME Industry Supported Session**

The Continuum of Heart

Supported by: Boehringer Ingelheim

**Robert J. Mentz, MD**



**SESSION 7**

**PRACTICE RECOMMENDATIONS IN DIABETES & ASCVD – AN UPDATE**

**Chairs:** Lawrence A. Leiter, MD • Sergio Fazio, MD, PhD

2:15pm – 2:30pm

Contemporary Lipid Management Recommendations in the Prevention of CVD

**Christie M. Ballantyne, MD**

2:30pm – 2:45pm

ESC/EASD 2019 CVD in DM Guidelines

**Peter J. Grant, MD**

2:45pm – 3:00pm

ADA-EASD Practice Recommendations 2019 Update

**David A. D'Alessio, MD**

3:00pm – 3:15pm

AACEDM & Lipid Practice Recommendations

**Yehuda Handelsman, MD**

3:15pm – 3:35pm

Panel Discussion & Live Q&A

**CME SUPPORTED SYMPOSIUM: THE PREVENTION AND MANAGEMENT OF HEART FAILURE**

**BY: ASTRAZENCA**

**Chairs:** Yehuda Handelsman, MD • Javed Butler, MD



3:35pm – 3:40pm Introduction

3:40pm – 4:00pm Epidemiology and Pathophysiology of HF

4:00pm – 4:20pm Preventing HF & HF Adverse Outcomes: A Look at the Evidence

4:20pm – 4:40pm The Present and Future Management of HFrEF and HFpEF

4:40pm – 4:55pm **Panel Discussion:** Practical Management of HF – Case-Based

**Panel:** Biykem Bozkurt, MD, PhD • Yehuda Handelsman, MD • Mikhail N. Kosiborod, MD  
Christian W. Mende, MD • Muthiah Vaduganathan, MD

**Moderator:** Javed Butler, MD

4:55pm – 5:15pm Live Q&A

**Mikhail N. Kosiborod, MD**

**Javed Butler, MD**

**Biykem Bozkurt, MD, PhD**

**5:15PM – 6:15PM**

**DAY 2 SUMMARY, LIVE Q&A**

**SUNDAY AUGUST 23, 2020**

**SESSION 8**

**MANAGEMENT OF HYPERGLYCEMIA TO IMPROVE OUTCOMES**

**Chairs:** Peter J. Grant, MD • Daniel Einhorn, MD

10:00am – 10:20am

Preventing Diabetes to Prevent CVD: Is it Chicken or Egg? (or Turkey?!)

**Silvio E. Inzucchi, MD**

10:20am – 10:40am

Managing Hyperglycemia in T2DM with Class 4-5 CKD

**Vivian A. Fonseca, MD**

10:40am – 11:00am

The Combination of SGLT2i and GLP1- $\alpha$ 's Impact on CVD

**Ralph A. DeFronzo, MD**

11:00am – 11:20am

Adjunctive Therapies for Type 1 Diabetes: Thinking Beyond Glucose Control

**Richard E. Pratley, MD**

11:20am – 11:40am

Panel Discussion & Live Q&A

**SESSION 9**

**THE TREATMENT OF DIABETES**

**Chairs:** Ralph A. DeFronzo, MD • Vivian A. Fonseca, MD

**DEBATE: EARLY COMBINATION VS SEQUENTIAL THERAPY - IMPACT ON DM & CVD**

11:40am – 12:00pm

Sequential Therapy

**David M. Nathan, MD**

12:00pm – 12:20pm

Early Combination Therapy

**Stefano Del Prato, MD**

12:20pm – 12:45pm

Panel, Q&A, Audience Voting

**12:45PM – 1:30PM**

**PRODUCT THEATER Non-CME Industry Supported Session**

The Next Horizon in the Heart Failure Treatment Paradigm for Patients with HFrEF: Results of the Landmark DAPA-HF Clinical Trial

Supported by: AstraZeneca

**Johanna Contreras, MD**



**SESSION 10**

**HEART IN DIABETES WITH JACC**

**Chairs:** Michael E. Farkouh, MD

1:30pm – 1:35pm

Introduction

**Michael E. Farkouh, MD**

1:35pm – 1:50pm

Atrial Fibrillation and Diabetes Mellitus

**Allen Wang, MD**

1:50pm – 2:05pm

Therapeutic Care, Health-Related Quality of Life, & Clinical Outcomes

in Comorbid HFrEF and DM: The CHAMP-HF Registry

**Muthiah Vaduganathan, MD**

2:05pm – 2:20pm

Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes

**Daniel Gudbjartsson, PhD**

2:20pm – 2:35pm

SGLT2 Inhibition and Cardiorenal Protection

**Julie A. Lovshin, MD, PhD**

2:35pm – 2:50pm

Individualizing Revascularization Strategy for Diabetic Patients with Multivessel CAD

**David J. Cohen, MD**

2:50pm – 3:10pm

Panel, Live Q&A



**SESSION 11**

**HEART FAILURE: STATE-OF-THE-ART**

**Chairs:** Matthew J. Budoff, MD • Mikhail N. Kosiborod, MD

- 3:10pm – 3:30pm Impact of Blood Pressure Variability on CHF
- 3:30pm – 3:50pm HF in DM - Is it Morbidity Not Mortality We Need to Focus on?
- 3:50pm – 4:10pm Physiologic Monitoring of Heart Failure
- 4:10pm – 4:30pm DAPA-HF and Next Steps with SGLT2 Inhibitors in Heart Failure
- 4:30pm – 5:00pm Panel Discussion & Live Q&A

Peter Reaven, MD  
 Mark Kearney, MD  
 Robert J. Chilton, DO  
 John McMurray, MD

**5:00PM – 6:00PM DAY 3 SUMMARY, LIVE Q&A**

**MONDAY, AUGUST 24, 2020**

**SESSION 12**

**GLP1-RA IN ASCVD & THE KIDNEY**

**Chairs:** Richard E. Pratley, MD • Matthew R. Weir, MD

- 10:00am – 10:20am Mechanistic Insights into Cardiovascular Effects of GLP1-ra
- 10:20am – 10:40am GLP1-ra Impact on the Kidney
- 10:40am – 10:55am Role of GLP1-ra in Trials in HF Patients
- 10:55am – 11:15am Panel Discussion & Live Q&A

Nikolaus Marx, MD  
 Mark E. Cooper, AO, PhD  
 Javed Butler, MD

**SESSION 13**

**THE KIDNEY & THE HEART**

**Chairs:** Christian W. Mende, MD • Robert J. Chilton, DO

- 11:15am – 11:35am The Role of Sodium Restriction in HF in Type 2 Diabetes
- 11:35am – 11:55am Effect of SGLT2i on BP and CKD Progression: Is it Dependent or Independent of BP?
- 11:55am – 12:15pm How Do SGLT2i Reduce Cardiorenal Outcomes and Atrial Fibrillation
- 12:15pm – 12:35pm Impact of Kidney Function on Mortality in the CVOTs
- 12:35pm – 1:00pm Panel Discussion & Live Q&A

Jeffrey Testani, MD  
 Matthew R. Weir, MD  
 Subodh Verma, MD, PhD  
 George L. Bakris, MD

**1:00PM – 1:45PM EXHIBIT HALL HOUR**

**SESSION 14**

**TECHNOLOGY & DIGITAL HEALTH**

**Chair:** Christos S. Mantzoros, MD, PhD

- 1:45pm – 2:05pm Artificial Intelligence in the Future Management of Cardiovascular Disease and Diabetes
- 2:05pm – 2:25pm The Implication of Digital Health for Cardiometabolic Conditions
- 2:25pm – 2:45pm Is There an App for That? Role of Devices on Diabetes and CVD Management
- 2:45pm – 3:00pm Panel Discussion & Live Q&A

Irving K. Loh, MD  
 Michael P. Snyder, PhD  
 George Grunberger, MD

**SESSION 15**

**THE LIVER & THE HEART**

**Chair:** Zachary T. Bloomgarden, MD

- 3:00pm – 3:20pm NAFLD & the Heart as a Part of the Spectrum of Cardiometabolic Risk
- 3:20pm – 3:40pm Emerging Management Options for NAFLD/NASH - Impact on Cardiometabolic Outcomes
- 3:40pm – 3:55pm Panel Discussion & Live Q&A

Laurence Sperling, MD  
 Christos S. Mantzoros, MD, PhD

**3:55pm – 4:55pm**

**ABSTRACT ORAL PRESENTATIONS**

**2020 Abstract Committee:** George Grunberger, MD Chair • Zachary T. Bloomgarden, MD • Matthew J. Budoff, MD  
 Vivian A. Fonseca, MD • Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Laurence Sperling, MD  
 Abstracts will be published in **American Heart Journal** Editor-in-Chief: **Daniel Mark, MD, MPH**

**4:55pm – 5:00pm ORAL ABSTRACT WINNERS AWARD PRESENTATION**

**5:00PM – 6:00PM DAY 4 SUMMARY, LIVE Q&A**

# FACULTY 2020



## Yehuda Handelsman, MD FACP, FNLA, FASPC, MACE

Chair & Program Director  
4th Heart in Diabetes  
Medical Director & Principal Investigator  
The Metabolic Institute of America  
Tarzana, California



## Mikhail N. Kosiborod MD, FACC, FAHA

Chair & Program Director  
4th Heart in Diabetes  
Professor of Medicine  
Saint Luke's Mid America Heart Institute  
University of Missouri-Kansas City  
School of Medicine  
Kansas City, Missouri



## George L. Bakris, MD, MA Hon. DSc, FASN, FAHA

Professor of Medicine  
Director, AHA Comprehensive  
Hypertension Center  
The University of Chicago Medicine  
Chicago, Illinois



## Christie M. Ballantyne, MD FACP, FACC

Chief, Sections of Cardiology and  
Cardiovascular Research  
Professor, Departments of Medicine  
Genetics and Physiology  
Director, Center for Cardiometabolic  
Disease Prevention  
Baylor College of Medicine  
Houston, Texas



## Richard C. Becker, MD, FAHA

Professor of Medicine  
Director, Division of Cardiovascular Health  
and Diseases  
Director and Physician-in-Chief  
University of Cincinnati Heart  
Lung & Vascular Institute  
University of Cincinnati  
College of Medicine  
Cincinnati, Ohio



## Joshua Beckman, MD, MS

Professor of Medicine  
Director, Vascular Medicine Section  
Vanderbilt Translational and Clinical  
Cardiovascular Research Center (VTRACC)  
Vanderbilt University Medical Center  
Nashville, Tennessee



## Deepak L. Bhatt, MD, MPH FACC, FAHA, FSCAI, FESC

Executive Director of Interventional  
Cardiovascular Programs,  
Brigham and Women's Hospital  
Heart & Vascular Center  
Professor of Medicine,  
Harvard Medical School  
Boston, Massachusetts



## Zachary Bloomgarden, MD MACE

Editor, the Journal of Diabetes  
[www.jdiabetes.com](http://www.jdiabetes.com),  
Clinical Professor  
Icahn School of Medicine at Mount Sinai  
New York, New York



## Biykem Bozkurt, MD, PhD FHFA, FACC, FAHA, FESC FACP

President, Heart Failure  
Society of America  
The Mary and Gordon Cain Chair  
"Tex" and Deborah Moncrief, Jr., Chair  
Professor of Medicine  
Medical Care Line Executive  
DeBakey VA Medical Center  
Director, Winters Center for  
Heart Failure Research  
Associate Director  
Cardiovascular Research Institute  
Vice-Chair of Medicine  
Baylor College of Medicine  
Houston, Texas



## Eugene Braunwald, MD

Distinguished Hersey Professor of  
Medicine Harvard Medical School  
Founding Chairman, TIMI Study Group  
Brigham and Women's Hospital  
Boston, Massachusetts



## Matthew J. Budoff, MD FACC, FAHA

Professor of Medicine  
David Geffen School of Medicine at UCLA  
Endowed Chair of Preventive Cardiology  
Program Director, Director of Cardiac CT  
Lundquist Institute  
Harbor-UCLA Medical Center  
Division of Cardiology  
Los Angeles, California



## Javed Butler, MD, MPH, MBA

Patrick H. Lehan Chair in  
Cardiovascular Research  
Professor and Chairman,  
Department of Medicine  
University of Mississippi Medical Center  
Jackson, Mississippi



## Robert J. Chilton, DO, FACP, FACC, FAHA, MACOI, FASCAI

Professor of Medicine  
Department of Medicine  
Division of Cardiology  
The University of Texas  
Health Science Center  
San Antonio, Texas



## David J. Cohen, MD, MSc

Professor of Medicine  
University of Missouri-Kansas City  
Kansas City, Missouri



## Mark E. Cooper, MB BS, PhD, FRACP

Head, Department of Diabetes  
Central Clinical School  
Monash University  
Senior Endocrinologist  
Alfred Health Clinic  
Melbourne, Australia



## David A. D'Alessio, MD

Professor of Medicine  
Chief, Division of Endocrinology  
Metabolism and Nutrition  
Associate Director, Duke Molecular  
Physiology Institute  
Durham, North Carolina



## Michael H. Davidson, MD FACC, FACP, FNLA

Professor, Director of the Lipid Clinic  
The University of Chicago Pritzker  
School of Medicine  
Chicago, Illinois



## Ralph A. DeFronzo, MD

Professor of Medicine  
Chief, Diabetes Division  
University of Texas Health Science Center  
at San Antonio (UTHSCSA)  
Deputy Director, Texas Diabetes Institute  
San Antonio, Texas

# FACULTY 2020



## Stefano Del Prato, MD

Professor of Endocrinology and Metabolism  
Chief of the Section of Diabetes  
University of Pisa, School of Medicine  
Pisa, Italy



## Daniel Einhorn, MD

FACP, FACE

President, Diabetes and Endocrine Associates Medical Director  
Scripps Whittier Diabetes Institute  
Past President, American Association of Clinical Endocrinology  
Past President, American College of Endocrinology (ACE)  
Associate Editor, Journal of Diabetes  
La Jolla, California



## Michael E. Farkouh, MD MSc, FRCPC, FACC, FAHA

Peter Munk Chair in Multinational Clinical Trials  
Director, Heart & Stroke Richard Lewar Centre of Excellence,  
University of Toronto  
Vice-Chair Research & Professor of Medicine, Department of Medicine  
University of Toronto  
Toronto, Ontario, Canada



## Sergio Fazio, MD, PhD

The William and Sonja Connor Chair of Preventive Cardiology  
Professor of Medicine and Physiology & Pharmacology  
Director, Center for Preventive Cardiology  
Knight Cardiovascular Institute  
Oregon Health & Science University  
Portland, Oregon



## Vivian A. Fonseca, MD, FRCP

Professor of Medicine and Pharmacology  
Assistant Dean for Clinical Research  
Tullis Tulane Alumni Chair in Diabetes  
Chief, Section of Endocrinology  
Tulane University Health Sciences Center  
New Orleans, Louisiana



## Peter J. Grant, MD FRCP, FMedSci

Professor of Medicine and Diabetologist  
Honorary Consultant Physician,  
Leeds Teaching Hospitals NHS Trust  
Division of Cardiovascular & Diabetes Research  
University of Leeds  
Leeds, United Kingdom



## George Grunberger, MD FACP, FACE

Chairman, Grunberger Diabetes Institute  
Clinical Professor, Internal Medicine and Molecular Medicine & Genetics  
Wayne State University  
School of Medicine  
Professor, Internal Medicine  
Oakland University William Beaumont  
Visiting Professor, Internal Medicine  
First Faculty of Medicine  
Charles University,  
Prague, Czech Republic  
Bloomfield Hills, Michigan



## Daniel Gudbjartsson, PhD

V.P. of Statistics  
deCODE Genetics  
Reykjavik, Iceland



## Mansoor Husain, BSc FRCPC, MD

Executive Director,  
Ted Rogers Centre for Heart Research  
Director, Toronto General Hospital  
Research Institute,  
University Health Network  
Professor, Department of Medicine,  
University of Toronto  
Senior Scientist, Toronto General Hospital  
Research Institute,  
University Health Network  
Toronto, Canada



## Silvio E. Inzucchi, MD

Professor of Medicine  
Yale School of Medicine  
Clinical Chief, Endocrinology and Medical Director  
Yale Diabetes Center  
Yale-New Haven Hospital  
New Haven, Connecticut



## Paul S. Jellinger, MD, MACE

Professor of Clinical Medicine  
Voluntary Faculty  
University of Miami  
Miller School of Medicine  
The Center for Diabetes & Endocrine Care  
Past President, AACE & ACE  
Hollywood, Florida



## Mark Kearney, MBChB MRCP, MD

British Heart Foundation Professor of Cardiovascular and Diabetes Research  
Leeds Institute of Cardiovascular & Metabolic Medicine  
Dean of the School of Medicine  
University of Leeds  
Leeds, United Kingdom



## Lawrence A. Leiter, MDCM FRCPC, FACP, FACE, FAHA

Associate Scientist,  
Li Ka Shing Knowledge Institute  
Director, Lipid Clinic Associate  
Director, Clinical Nutrition and Risk Factor Modification Centre  
St. Michael's Hospital  
Professor, Medicine and Nutritional Sciences  
University of Toronto  
Toronto, Canada



## Norman E. Lepor, MD, FACC

Clinical Professor of Medicine  
David Geffen School of Medicine at UCLA  
Attending Cardiologist at the Smidt Cedars-Sinai Heart Institute  
Director of Clinical Research  
Westside Medical Associates of LA  
Co-Director of Cardiovascular Imaging  
Westside Medical Imaging in Beverly Hills  
Los Angeles, California



## Derek LeRoith, MD, PhD FACP

Professor of Medicine  
Director of Research  
Division of Endocrinology  
Diabetes & Bone Disease  
Department of Medicine  
Icahn School of Medicine at Mt. Sinai  
New York, New York



# FACULTY 2020



## Alice H. Lichtenstein, D.Sc.

Gershoff Professor of Nutrition Science and Policy  
Director and Senior Scientist  
Cardiovascular Nutrition Laboratory  
Tufts University  
JM USDA Human Nutrition Research Center on Aging  
Executive Editor, Tufts Health and Nutrition Letter  
Boston, Massachusetts



## Myra A. Lipes, MD

Assistant Professor, Medicine  
Harvard Medical School  
Assistant Professor, Medicine,  
Brigham And Women's Hospital  
Investigator, Research Division  
Joslin Diabetes Center  
Boston, Massachusetts



## Irving Kent Loh MD

FACC, FAHA, FCCP, FACP  
Chief Medical Officer and Co-Founder,  
INFERMEDICA  
Ventura Heart Institute  
Chair, Technology & Innovation,  
California Chapter,  
American College of Cardiology  
Member, AI4H, International  
Telecommunication Union, World Health  
Organization/UN  
Adjunct Lecturer, Department of  
Medicine, Stanford University  
School of Medicine  
Thousand Oaks, California



## Julie A. Lovshin, MD, PhD FRCPC

Clinician Scientist  
Assistant Professor of Medicine  
Division of Endocrinology & Metabolism  
University of Toronto  
Sunnybrook Health Sciences Centre  
Toronto, Ontario, Canada



## Gina P. Lundberg, MD FACC, FAHA

Clinical Director  
Emory Women's Heart Center  
Associate Professor of Medicine  
Emory University School of Medicine  
Division of Cardiology  
Atlanta, Georgia



## Christos S. Mantzoros, MD DSc, PhD h.c. mult.

Professor of Medicine  
Harvard Medical School and Boston  
University School of Medicine  
Chief of Endocrinology,  
Diabetes and Metabolism  
Boston VA Healthcare System  
Director of Human Nutrition, Beth Israel  
Deaconess Medical Center  
Editor-in-Chief, Metabolism  
Clinical & Experimental  
Boston, Massachusetts



## Nikolaus Marx, MD FESC, FAHA

Professor of Medicine / Cardiology  
Head of the Department of  
Internal Medicine  
University Hospital RWTH Aachen  
Aachen, Germany



## John McMurray, BSC (Hons) MB ChB (Hons), MD, FRCP FESC, FACC, FAHA, FRSE FMedSci, OBE

Professor of Medical Cardiology and  
Deputy Director (Clinical)  
Institute of Cardiovascular and  
Medical Sciences  
Honorary Consultant Cardiologist  
Queen Elizabeth University Hospital  
Glasgow, Scotland



## Christian W. Mende, MD FACP, FACN, FASN, FASH, FAHA

Clinical Professor of Medicine  
University of California San Diego  
La Jolla, California



## Robert J. Mentz, MD FACC, FAHA, FHFSa

Associate Professor of Medicine  
Chief, Heart Failure Section  
Associate Program Director,  
Duke Cardiovascular Disease Fellowship  
Duke University Medical Center and  
Duke Clinical Research Institute  
Durham, North Carolina



## David M. Nathan, MD

Director, Diabetes Center and  
Clinical Research Center  
Massachusetts General Hospital  
Professor of Medicine  
Harvard Medical School  
Boston, Massachusetts



## Steven E. Nissen, MD, MACC

Chief Academic Officer  
Heart and Vascular Institute  
Cleveland Clinic  
Professor of Medicine  
Cleveland Clinic Lerner  
School of Medicine  
at Case Western Reserve University  
Cleveland, Ohio



## Neha J. Pagidipati, MD, MPH

Assistant Professor of Medicine,  
Division of Cardiology  
Director, Duke Cardiometabolic  
Prevention Program  
Associate Program Director  
Cardiology Fellowship  
Associate Program Director  
DCRI Research Fellowship  
Duke Clinical Research Institute  
Duke University Medical School  
Durham, North Carolina



## Richard E. Pratley, MD

Samuel E. Crockett  
Chair in Diabetes Research  
Medical Director, AdventHealth  
Diabetes Institute  
Senior Investigator and  
Diabetes Program Lead  
AdventHealth Translational  
Research Institute  
Orlando, Florida

# FACULTY 2020



**Kausik Ray, BSc(hons)  
MBChB, MD, MPhil (Cantab)  
FRCP (Lon), FRCP (Ed), FACC  
FESC, FAHA**

Professor of Public Health  
Consultant Cardiologist  
Deputy Director of The Imperial Clinical  
Trials Unit Head of Commercial Trials  
Department of Public  
Health & Primary Care  
School of Public Health, Imperial College  
NIHR ARC National Lead of  
Cardiovascular Disease  
EAS President Elect  
London, United Kingdom



**Peter Reaven, MD**

Professor of Clinical Medicine  
University of Arizona  
Director, Diabetes Program  
Carl T. Hayden VAMC (111E)  
Research Professor  
College of Health Solutions  
Arizona State University  
Phoenix, Arizona



**Jennifer G. Robinson, MD, MPH**

Professor, Departments of  
Epidemiology & Medicine  
Director, Prevention Intervention Center  
Carver College of Medicine  
University of Iowa  
Iowa City, Iowa



**Benjamin M. Scirica, MD, MPH**

Associate Professor of Medicine, Harvard  
Medical School  
Associate Physician  
Brigham and Women's Hospital  
Senior Investigator, TIMI Study Group  
Boston, Massachusetts



**Michael P. Snyder, PhD**

Professor and Chair of Genetics  
Director, Center for Genomics and  
Personalized Medicine  
Stanford University School of Medicine  
Stanford, California



**Laurence Sperling, MD**

**FACC, FAHA, FACP, FASPC**  
Katz Professor in Preventive Cardiology  
Director of the Emory Heart Disease  
Prevention Center  
Professor of Global Health  
Hubert Department of Global Health  
Rollins School of Public Health at  
Emory University  
Atlanta, Georgia



**Philippe Gabriel Steg, MD  
FESC, FACC**

Chief, Department of Cardiology  
Hôpital Bichat, Assistance Publique-  
Hôpitaux de Paris  
Vice President  
Board of the Assistance Publique-  
Hôpitaux de Paris  
Professor of Cardiology,  
Université Paris - Diderot  
Director, "Clinical Research in  
Atherothrombosis" Research Team  
Coordinator of the iVASC (InnoVations in  
Atherothrombosis Science)  
RHU research consortium  
Chair of the FACT  
Chairman of the French National  
University Council  
Paris, France



**Jeffrey Testani, MD, MTR**

Associate Professor  
Director of Heart Failure Research,  
Section of Cardiovascular Medicine  
Yale University School of Medicine  
New Haven, Connecticut



**Muthiah Vaduganathan, MD,  
MPH**

Cardiologist, Brigham and  
Women's Hospital  
Instructor of Medicine  
Harvard Medical School  
Boston, Massachusetts



**Subodh Verma, MD, PhD  
FRCS, FAHA**

Cardiac Surgeon  
Professor of Surgery and  
Pharmacology & Toxicology  
University of Toronto  
Canada Research Chair in  
Cardiovascular Surgery  
Division of Cardiac Surgery  
St. Michael's Hospital  
Toronto, Ontario, Canada



**Allen Wang, MD**

Duke Center for Atrial Fibrillation  
Department of Medicine  
Duke University Medical Center  
Durham, North Carolina



**Matthew R. Weir, MD**

Professor and Chief  
Nephrology Division  
Department of Medicine  
University of Maryland  
School of Medicine  
Baltimore, Maryland

## HEART IN DIABETES PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Mikhail N. Kosiborod, MD, Chair • Deepak L. Bhatt, MD • Zachary T. Bloomgarden, MD • Biykem Bozkurt, MD, PhD  
Matthew J. Budoff, MD • Javed Butler, MD • David Cherney, MD, PhD • Robert J. Chilton, DO • Mark E. Cooper, AO, PhD  
Michael H. Davidson, MD • Ralph A. DeFronzo, MD • Daniel Einhorn, MD • Michael E. Farkouh, MD • Sergio Fazio, MD, PhD • Vivian A. Fonseca, MD  
Alan J. Garber, MD, PhD • Peter J. Grant, MD • George Grunberger, MD • Silvio E. Inzucchi, MD • Paul S. Jellinger, MD • Mark Kearney, MD • Lawrence A. Leiter, MDCM  
Norman E. Lepor, MD • Derek LeRoith, MD, PhD • Christos S. Mantzoros, MD, DSc, PhD • Nikolaus Marx, MD • Darren K. McGuire, MD  
Christian W. Mende, MD • Richard E. Pratley, MD • Kausik Ray, MD • Peter Reaven, MD • Laurence Sperling, MD • Matthew R. Weir, MD • Renee S. Asp, BS



**ATTENDANCE IS FREE!**  
**Free Registration • Free CME**  
**[www.heartindiabetes.com/registration](http://www.heartindiabetes.com/registration)**  
**Email: [info@tmioa.com](mailto:info@tmioa.com)**  
**To register by phone: (818) 342-1889**

## **CME ACCREDITATION**

This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

### **AMA PRA Designation Statement**

The PESI Inc. designated this live activity for a maximum of 28 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### **MOC Points with ABIM**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 28 MOC points of Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

### **International CME**

International Physicians are formally eligible for AMA PRA Category 1 Credit<sup>™</sup>.

### **Physician Assistants**

AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit<sup>™</sup> for the PRA from organizations accredited by ACCME.

### **Nurses**

For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit<sup>™</sup> issued by organizations

accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

### **CA Nurses**

Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 4th HiD for approximately 28 contact hours.

### **Pharmacists**

For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit<sup>™</sup> issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

### **CDE**

The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. This course qualifies for 28 continuing education hours.

### **Registered Dietitian**

For the purpose of recertification, the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit<sup>™</sup>.

### **Satisfactory Completion for credits**

All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.

## ENDORISING ORGANIZATIONS:

- American Association of Diabetes Educators (AADE)
- Association of Diabetes Care & Education Specialists (ADCES)
- American Society of Endocrine Physician Assistants (ASEPA)
- American Society for Preventive Cardiology (ASPC)
- California Chapter of the American College of Cardiology (CAACC)
- Endocrine Nurses Society (ENS)
- FH Foundation
- International Academy of Cardiology (IAC)
- International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
- Israel Endocrine Society (IES)
- National Lipid Association (NLA)
- Society for Vascular Surgery (SVS)
- World Obesity Federation

## MEDIA PARTNERS:

- American Heart Journal (Elsevier)
- Healio (Cardiology Today & Endocrine Today)
- Metabolism (Elsevier)
- Bentham Science
- Cardiology Advisor
- Cardiovascular, Endocrinology & Metabolism (Wolters Kluwer)
- CN1699
- Conference Locate
- Current Opinion in Endocrinology, Diabetes & Obesity (Wolters Kluwer)
- Diabetes in Control
- Diabetes Research and Clinical Practice (Elsevier)
- Diabetes & Vascular Disease Research (Sage)
- Endocrine Web
- Hindawi
- Journal of Diabetes
- Lancet Diabetes & Endocrinology
- MIMS
- PharmaVoice
- Physician's Weekly
- VenurDir
- Vessel Plus

For additional information on  
**REGISTRATION • SUPPORT • EXHIBITS**  
**(818) 342-1889 | [info@tmioa.com](mailto:info@tmioa.com) | [www.heartindiabetes.com](http://www.heartindiabetes.com)**

**SAVE THE DATE**  
**5th ANNUAL | HEART IN DIABETES**  
**Live CME Conference | June 18-20, 2021**  
**Grand Hyatt, New York City**

